Call Us: 1.800.873.5297


MDL 2404 Update: Nexium® Lawsuits on the Rise

On December 6, 2012, lawsuits filed in federal court against the manufacturers of Nexium® were consolidated by the Judicial Panel on Multidistrict Litigation (JPML) in order to coordinate federal judicial proceedings. This Multidistrict Litigation (MDL) is entitled In re: Nexium® (Esomeprazole) Products Liability Litigation (MDL 2404) and is currently pending in the United States District […]


Celgene Stops Late-Stage Trial of Revlimid® Due to High Mortality Rates

According to a recent report, Celgene has announced that it will stop a late-stage trial of its blood cancer drug, Revlimid®, after observing more deaths in elderly leukemia patients taking the drug as compared to those patients using an alternative treatment. The trial sought to test Revlimid® in formerly untreated, elderly patients with B-cell chronic […]


Lawyers Seek Consolidation of Diabetes Drug Lawsuits in Federal Court

Last Thursday, attorneys urged the Judicial Panel on Multidistrict Litigation (JPML) to consolidate over fifty diabetes drug lawsuits in the United States District Court for the Southern District of California. These lawsuits involve four diabetes drugs in particular: Janumet® and Januvia®, manufactured by Merck Sharpe & Dohme; Victoza®, manufactured by Novo Nordisk Inc.; and Byetta®, […]


Actos® Lawsuit Update: First Actos® Trial in Cook County, Illinois Set for March 2014

There are over 2,600 Actos® bladder cancer cases currently on file against Takeda Pharmaceuticals in Cook County Circuit Court in Chicago, Illinois before The Honorable Judge Deborah Mary Dooling (In re Actos Litigation, Case No. 2011 L 10011). The first trial in the Cook County Actos® litigation is scheduled to begin in March 2014. Actos® […]


Plavix® Lawsuits Pending in New Jersey MDL

Plaintiffs throughout the country have filed lawsuits against drug makers Bristol-Myers Squibb and Sanofi-Aventis claiming they have suffered various injuries from the use of Plavix®, including cerebral hemorrhaging (brain bleeding) and gastrointestinal hemorrhaging (abdominal bleeding). Plavix® was approved in 1997 and is commonly prescribed to patients at risk for heart attack, stroke, or blood clotting. […]


Number of Pradaxa® Lawsuits on the Rise

Since May of this year, 470 new Pradaxa® lawsuits have been added to the Multidistrict Litigation In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385), which is currently pending in the United States District Court for the Southern District of Illinois before the Honorable Chief Judge David R. Herndon. The number of lawsuits joined […]


Eighth Circuit Permits Design Defect Claim Against Reglan® Generics To Proceed

On Monday, the United States Court of Appeals for the Eighth Circuit reopened a personal injury lawsuit against Pliva Inc. and Mutual Pharmaceutical Co., manufacturers of generic Reglan®. In the lawsuit, Joyce Fullerton claims that she developed a neurological disorder involving involuntary movements from a generic form of Reglan®. Her complaint is one of hundreds […]


NuvaRing® Lawsuit Update: Plaintiffs Succeed in Defeating Defendants’ Summary Judgment Motion in NuvaRing® MDL

On July 12, United States District Court Judge Rodney Sippel handed down an order largely denying defendants’ summary judgment motion filed against the first bellwether trial plaintiff in the Multidistrict Litigation In re: NuvaRing® Products Liability Litigation (MDL No. 1964). In particular, the Honorable Judge Rodney Sippel ruled that plaintiff established genuine issues of material […]


New Diabetes Drug Discontinued Due to Safety Concerns

According to a recent report, Roche, a Swiss pharmaceutical company, announced that it is abandoning development of a diabetes drug known as aleglitazar. The announcement came after a safety monitoring committee recommended stopping a late-stage clinical trial of the drug due to “safety signals and lack of efficacy.” Roche ultimately decided to halt the study […]


Benicar® Blood Pressure Medication May Cause Serious Intestinal Problems

On July 3, 2013, the FDA issued a drug safety communication for all medications containing the active ingredient, olmesartan medoxomil. Benicar® belongs to a class of medications known as angiotension II receptor blockers (ARBs), approved to treat high blood pressure. Although the blood pressure drug is best known under the brand name, Benicar®, it is also […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.